The effects of total pleural covering on pneumothorax recurrence and pulmonary function in lymphangioleiomyomatosis patients without history of pleurodesis or thoracic surgeries for pneumothorax.
Total pleural covering (TPC)
lymphangioleiomyomatosis (LAM)
mTOR inhibitor
pneumothorax
pulmonary function
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
12
2
2021
Statut:
ppublish
Résumé
Total pleural covering (TPC) is an innovative surgical procedure in which the entire visceral pleura is wrapped with sheets of oxidized regenerated cellulose (ORC) mesh under video-assisted thoracoscopic surgery. We have previously reported that TPC could successfully prevent pneumothorax recurrence in patients with lymphangioleiomyomatosis (LAM). However, the actual efficacy and preventive effect of TPC on pneumothorax recurrence remains unclear as many LAM patients already had pleural adhesion prior to TPC that was induced by thoracic surgery and/or pleurodesis. The purpose of this study is to evaluate the effects of TPC on pneumothorax recurrence and pulmonary function in LAM patients with no history of thoracic surgeries or pleurodesis. We retrospectively reviewed medical charts of 52 patients (60 hemithoraces) who underwent TPC at our center, from January 2003 to September 2019, as a first surgical intervention for pneumothorax. Pneumothorax recurrence occurred in 12 patients [14 of 60 hemithoraces (23.3%)] during the observation period [27 months (14.7; 56.4) = median (lower; upper quartiles)]. The probability of recurrence-free hemithorax post TPC was 81.1% at 2.5 years and 64.1% at 5 years. TPC did not produce a significant decrease in either VC %predicted (pred) or FEV TPC can prevent pneumothorax recurrence without causing ventilatory impairment or severe pleural symphysis in LAM patients. TPC is an effective treatment option for LAM-associated pneumothorax based on its efficacy and safety.
Sections du résumé
BACKGROUND
BACKGROUND
Total pleural covering (TPC) is an innovative surgical procedure in which the entire visceral pleura is wrapped with sheets of oxidized regenerated cellulose (ORC) mesh under video-assisted thoracoscopic surgery. We have previously reported that TPC could successfully prevent pneumothorax recurrence in patients with lymphangioleiomyomatosis (LAM). However, the actual efficacy and preventive effect of TPC on pneumothorax recurrence remains unclear as many LAM patients already had pleural adhesion prior to TPC that was induced by thoracic surgery and/or pleurodesis. The purpose of this study is to evaluate the effects of TPC on pneumothorax recurrence and pulmonary function in LAM patients with no history of thoracic surgeries or pleurodesis.
METHODS
METHODS
We retrospectively reviewed medical charts of 52 patients (60 hemithoraces) who underwent TPC at our center, from January 2003 to September 2019, as a first surgical intervention for pneumothorax.
RESULTS
RESULTS
Pneumothorax recurrence occurred in 12 patients [14 of 60 hemithoraces (23.3%)] during the observation period [27 months (14.7; 56.4) = median (lower; upper quartiles)]. The probability of recurrence-free hemithorax post TPC was 81.1% at 2.5 years and 64.1% at 5 years. TPC did not produce a significant decrease in either VC %predicted (pred) or FEV
CONCLUSIONS
CONCLUSIONS
TPC can prevent pneumothorax recurrence without causing ventilatory impairment or severe pleural symphysis in LAM patients. TPC is an effective treatment option for LAM-associated pneumothorax based on its efficacy and safety.
Identifiants
pubmed: 33569191
doi: 10.21037/jtd-20-2286
pii: jtd-13-01-113
pmc: PMC7867849
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113-124Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (http://dx.doi.org/10.21037/jtd-20-2286). The authors have no conflicts of interest to declare.
Références
Orphanet J Rare Dis. 2018 Sep 21;13(1):168
pubmed: 30241551
Thorax. 2010 Aug;65 Suppl 2:ii18-31
pubmed: 20696690
Gen Thorac Cardiovasc Surg. 2016 Jul;64(7):425-8
pubmed: 25512090
N Engl J Med. 2011 Apr 28;364(17):1595-606
pubmed: 21410393
Gen Thorac Cardiovasc Surg. 2012 Jul;60(7):452-5
pubmed: 22544422
Am J Respir Crit Care Med. 2001 Sep 15;164(6):1072-6
pubmed: 11587999
Surg Today. 2011 Oct;41(10):1414-7
pubmed: 21922367
Gen Thorac Cardiovasc Surg. 2020 Oct;68(10):1208-1211
pubmed: 31612306
Orphanet J Rare Dis. 2018 May 15;13(1):78
pubmed: 29764481
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1337-1348
pubmed: 29140122
PLoS One. 2016 Sep 22;11(9):e0163637
pubmed: 27658250
Surg Today. 2018 Apr;48(4):462-472
pubmed: 29027010
Chest. 2008 Feb;133(2):507-16
pubmed: 18252917
Orphanet J Rare Dis. 2018 Dec 13;13(1):222
pubmed: 30545392
Chest. 2006 May;129(5):1274-81
pubmed: 16685019
Ann Thorac Cardiovasc Surg. 2017 Dec 20;23(6):309-312
pubmed: 28690286
Am J Respir Crit Care Med. 2003 Dec 15;168(12):1427-31
pubmed: 12958050
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542